fashion -WSS

fashion

author：explore 2025-09-28 23:05:42 - browse：756

A woman walks in San Francisco, with her father who has Alzheimer's – public health and science coverage from STAT — Ben Margot/AP

A host of hurdles are slowing the adoption of the new Alzheimer’s drug Leqembi, experts involved in the treatment of patients said Wednesday, from complicated logistics to the fact that many people don’t recognize that their memory loss is a disease soon enough.

Some patients still grapple with whether they want to be diagnosed, even though a treatment exists, the experts said, speaking during a STAT virtual event.

“Even the word for dementia does not always exist in every culture and in every language,” said Hollis Day, chief of geriatrics at Boston Medical Center and a professor at Boston University’s medical school. “And so just getting people to accept that memory loss is not normal aging necessarily, is a big barrier to getting people into diagnosis early enough to benefit from these treatments.”

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Peter Hotez and the public health issue of online harassment
Next article： Color Health wants to make cancer screenings convenient

WSS

Medicare isn't yet testing food as medicine

CDC panel: People 65 and older should get a Covid spring booster shot

Popular nasal decongestant doesn't actually relieve congestion

Readout Newsletter: GSK, Viking Therapeutics, mifepristone news

Medicare isn't yet testing food as medicine

'Vaccine

knowledge

fashion

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

focus

Psychedelics group wrestles with new pharma identity

Pfizer is about to make a big push in cancer. Will investors listen?

Over 800 arrested across France in 3rd night of riots after fatal police shooting of teen

Neuroscience renaissance leads to new crop of psychiatric drugs

Guidelines to prevent youth baseball injuries need more muscle

PEPFAR is under serious threat — and so is global health

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Acelyrin, a rare IPO success, stumbles in its first big test

Heart attack and stroke risk calculators need revising

Generate Biomedicines machine learning biotech raises $273M

explore

New weight loss drugs vying to be the next Wegovy or Mounjaro

How to make the FDA’s new prescription one

Children’s Hospital revives plan for pedestrian bridge

Generate Biomedicines machine learning biotech raises $273M

Telehealth for opioid use disorder is lifesaving

Laying a path for careers in science

focus

entertainment

focus

leisure time